GLP-1 Cost Without Insurance: Every Cash-Pay Route Compared
Without insurance, compounded semaglutide ($145-299) is usually cheapest, followed by oral Wegovy (from $149 for qualifying patients), brand self-pay via NovoCare/LillyDirect (~$299-349), and brand list (~$1,086-1,349). Compounded semaglutide from about $145 per month is usually the cheapest cash route, with brand self-pay near $349 as the FDA-approved alternative; total all mandatory fees and compare renewal, not introductory, pricing.
- Uninsured, compounded GLP-1s are usually the cheapest legitimate route.
- Oral Wegovy from ~$149/mo (qualifying patients, specified doses) is a competitive approved option.
- Brand self-pay (NovoCare ~$349, LillyDirect ~$299) buys the approved product.
- Model effective monthly cost after all fees, and confirm renewal pricing.
The cash-pay landscape
Without insurance, GLP-1 pricing spans an enormous range — from about $145 per month for compounded semaglutide to about $1,349 list for brand Wegovy. The route you choose depends on whether you prioritize the lowest price or an FDA-approved product.
Cash pricing does not vary by state; it is set by the provider or manufacturer nationally. So the decision is about product type, not geography.
Compounded: usually cheapest
Compounded semaglutide from about $145 per month and compounded tirzepatide from about $199 are the lowest-cost legitimate routes for most uninsured patients. The trade-off is that these are not FDA-approved and carry no formulation-specific trial evidence.
Verify the dispensing pharmacy is named and state-licensed before enrolling, and confirm there is no hidden membership that inflates the effective cost.
| Route | Monthly | FDA-approved? |
|---|---|---|
| Compounded semaglutide | $145–299 | No |
| Oral Wegovy (qualifying) | from $149 | Yes |
| Compounded tirzepatide | $199–297 | No |
| Brand self-pay | $299–349 | Yes |
| Brand list | $1,086–1,349 | Yes |
Brand self-pay options
For patients who want the approved product without insurance, manufacturer self-pay programs are the route. NovoCare offers Wegovy near $349 per month; LillyDirect offers Zepbound vials from about $299. The oral Wegovy tablet is available from about $149 per month for qualifying patients at specified doses, though promotional pricing can change and some offers have expiration dates.
These cost more than compounded but deliver FDA-approved medication with full trial backing.
| Route | Trade-off |
|---|---|
| Compounded | Cheapest, not FDA-approved |
| Oral Wegovy | Approved pill, dose-limited pricing |
| Brand self-pay | Approved, higher cost |
Ranked by cost
For a cash-pay patient, the rough ranking is: compounded semaglutide (lowest), oral Wegovy for qualifying patients, compounded tirzepatide, brand self-pay via LillyDirect or NovoCare, and brand list (highest, and rarely what anyone should pay). Your clinician determines which is appropriate for you.
The cheapest option is not automatically best: weigh pharmacy transparency, dose coverage, and whether you need an approved product against the price difference.
Frequently asked questions
What is the cheapest GLP-1 without insurance?
Compounded semaglutide from about $145/month is usually the cheapest legitimate route, though it is not FDA-approved.
Is there an approved option under $200?
The oral Wegovy tablet is available from about $149/month for qualifying patients at specified doses, though offers can change and expire.
Does cash price vary by state?
No. GLP-1 cash pricing is set nationally by the provider or manufacturer; it does not change by state.
Sources
- FDA — human drug compounding and GLP-1 status.
- NovoCare and LillyDirect pricing, captured July 2026.
- Evidence ledger: evidence-ledger.csv.